Associations of intermuscular adipose tissue and total muscle wasting score in PG-SGA with low muscle radiodensity and mass in nonmetastatic colorectal cancer: A two-center cohort study

Yang Wang¹, Yuliuming Wang¹, Guodong Li², Hao Zhang¹, Hang Yu¹, Jun Xiang¹, Zitong Wang¹, Xia Jiang¹, Guoqing Yan¹, Yunxiao Liu¹, Chunlin Wang¹, Huan Xiong¹, Guiyu Wang¹, Hanping Shi³ and Ming Liu¹*

Backgrounds: The patient-generated subjective global assessment (PG-SGA) is one of the screening criteria for malnutrition, the skeletal muscle radiodensity (SMD) and skeletal muscle mass index (SMI) are associated with survival in colorectal cancer patients. Body composition parameters can be easily assessed; however, few studies have examined the association between total muscle wasting scores in PG-SGA and body composition parameters and two muscle abnormalities.

Methods: This cohort study included 1,637 stage I-III CRC patients from 2 clinical centers in China, who were enrolled in the training cohort (n = 1,005) and validation cohort (n = 632). Baseline data were collected prospectively from patients including age, BMI, staging, gait speed, hand grip strength (HGS), peak expiratory flow (PEF), neutrophil-lymphocyte ratio (NLR), intermuscular adipose tissue (IMAT), visceral fat area (VFA) and total muscle wasting score in PG-SGA. Relevant risk factors were subjected to logistic regression analysis and Cox regression analysis to identify characteristics associated with muscle abnormalities and survival. Based on the logistic model results, nomograms were established to predict muscle abnormalities, and its discrimination and calibration were assessed using the receiver operating characteristic (ROC) curve and calibration curve. The Kaplan-Meier curves were used to assess the survival of colorectal cancer patients with malnutrition or sarcopenia in an inflammatory state (assessed by NLR).

Results: The mean age of all participants was 57.7 ± 10.6 years (56.9% males) and the prevalence of low SMD and low SMI was 32.2 and 39.5%, respectively. Low SMD rate was significantly associated with age, TNM stage, BMI, IMAT,
walking speed, total muscle wasting score and NRS2002 score by logistic regression analysis (p < 0.05). Low SMI rate was significantly correlated with age, NLR, BMI, PEF, handgrip strength, calf circumference, walking speed, total muscle wasting score and NRS2002 score (p < 0.05). The AUCs of the diagnostic nomograms were 0.859 (95% CI, 0.831–0.866) for low SMD and 0.843 (95% CI, 0.813–0.871) for low SMI in the validation cohort. We also found that patients with colorectal cancer with malnutrition or sarcopenia had a worse prognosis when NLR ≥3.5.

**Conclusion:** Muscle abnormalities and malnutrition are strongly associated with mortality in patients with non-metastatic colorectal cancer. Early identification and intervention of the associated risk factors may offer new ways to improve patient prognosis.

**KEYWORDS**

low muscle radiodensity, low muscle mass, total muscle wasting score, PG-SGA, intermuscular adipose tissue, nonmetastatic colorectal cancer

---

**Introduction**

Skeletal muscle is the organism’s effector organ for various simple and complex movements, accounting for about 40% of body weight, and it also plays an important role in the metabolism of carbohydrate, fat and protein (1, 2). Studies have shown that most tumor patients can experience varying degrees of muscle hypofunction and muscle atrophy at different stages of disease development (3), resulting in tumor-associated sarcopenia, which affects the normal metabolism of body components, resulting in higher rates of clinical complications, longer hospital stays, and lower prognosis for survival (4–6).

Globally, colorectal cancer (CRC) accounts for approximately one tenth of diagnosed and fatal cases of malignancy (7). In China, the National Cancer Center has recently reported that colorectal cancer is the second most common malignancy and the fourth most common mortality, and has shown an increasing trend in incidence and mortality since 2000–2016 (8). Cohort studies have shown that the prevalence of sarcopenia in colorectal cancer ranges from ~12–71% (9, 10). The two key components of skeletal muscle loss are quality and quantity, expressed by skeletal muscle radiodensity (SMD) and skeletal muscle mass index (SMI), respectively (11). Computed tomography (CT), long used in cancer diagnosis, is emerging as a cutting-edge strategy for quantifying low SMD and low SMI, while extracting highly accurate body composition data. For example, intermuscular adipose tissue (IMAT) can be obtained by CT (12), but to our knowledge, few studies have explored the association between intermuscular infiltration of excess fat and low SMD and SMI.

According to the expert consensus of the 2018 Annual Meeting, European Society of Parenteral and Enteral Nutrition (ESPEN) released the Global Leadership Initiative on Malnutrition (GLIM), guidelines stating that reduced muscle mass and low BMI are indicative of malnutrition (13). The PG-SGA also acts as a diagnostic tool for malnutrition and cancer cachexia (14), was developed according to ISPOR principles and is available for download (www.pt-global.org). In this work, we use the term total muscle wasting score to refer to the scored subjective rating of muscle mass in worksheet 4 of the PG-SGA (proposed by FD Ottrey et al.), and the study demonstrated that it allows clinicians to make a more visual, graded and dynamic determination of patients’ muscle status (15, 16). However, the PG-SGA total muscle wasting score is often overlooked in clinical practice and may be one of the most valid ways to determine low SMD and SMI.

Secondary prevention (i.e., prevention of complications after diagnosis) is one of the key strategies to reduce the heavy burden of colorectal cancer. Low SMD and low SMI are an emerging prognostic factor in colorectal and other cancers (9, 17, 18),

**Abbreviations:** PG-SGA, patient-generated subjective global assessment; CRC, colorectal cancer; CT, computed tomography; ESPEN, European Society of Parenteral and Enteral Nutrition; GLIM, Global Leadership Initiative on Malnutrition; EWGSOP-2, European Working Group on Sarcopenia in Older People 2; NCCN, National Comprehensive Cancer Network; NLR, neutrophil-lymphocyte ratio; CRP, C-reactive Protein; BMI, body mass index; TNM, tumor-node-metastasis; MUAC, mid-upper arm circumference; TSF, triceps skinfold thickness; MAMC, mid-arm muscle circumference; CC, Calf circumference; PEF, Peak expiratory flow; FEV1, Forced Expiratory Volume In 1s; VC, Vital Capacity; IMAT, intermuscular adipose tissue; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; L3, third lumbar vertebra; DCA, decision curve analysis; AUC, area under the curve; ROC, receiver-operating characteristic; HU, Hounsfield unit; SMD, skeletal muscle radiodensity; SMI, skeletal muscle index; LSMI, low skeletal muscle mass index; LSMD, low skeletal muscle radiodensity; NRS, nutritional risk screening; QLQ-C30, Quality of Life Questionnaire-Core 30.
Little is known about the risk factors for low SMD and low SMI in CRC. Recognizing and modifying these risk factors may help predict and improve the overall prognosis of colorectal cancer patients. The aim of this study was to investigate the associations of IMAT and total muscle wasting scores in PG-SGA with low SMD and low SMI, and we also comprehensively collected patients’ demographic characteristics, hematological parameters, anthropometric measurements, lung function, body composition parameters and nutritional status scores to explore other risk factors associated with low SMD, low SMI, and survival.

Subsequently, we constructed corresponding nomograms and assessed the survival of patients with non-metastatic colorectal cancer under different risk factors.

Materials and methods

Study population and setting

For our training dataset, we selected patients aged 18–85 years with stage I-III colorectal cancer who underwent radical surgery at the Fourth Hospital of Harbin Medical University from January 2014 to March 2017 for the prospective study. All pre-op patients underwent a standard nutritional status assessment (anthropometric measurements, hematology and nutritional status score, etc.), pulmonary function and abdominal CT scan. Inclusion criteria also included (1) patients with a histological diagnosis of colorectal adenocarcinoma; (2) patients who were conscious, without communication problems, and who agreed to participate in the study. Exclusion criteria include (1) local recurrence or ≥2 primary tumors; (2) no eligible preoperative CT scan available; (3) patients with acute medical conditions or a history of other tumors. For our validation dataset, we selected patients aged 18–85 years with stage I-III colorectal cancer undergoing radical surgery at the Second Hospital of Harbin Medical University from March 2020 to March 2022 with the same admission and exclusion criteria. The primary study outcome was the presence of low SMD and low SMI. The flowchart representing nonmetastatic colorectal cancer patient selection is shown in Figure 1. This study was approved by the ethics committee of the Second Hospital of Harbin Medical University and the Fourth Hospital of Harbin Medical University.

Data collection

Prospectively collect the following data from patients with non-metastatic colorectal cancer: (1) Demographic characteristics and tumor characteristics: sex, age, diabetes, smoking history (patient who had smoked more than 100 cigarette cumulatively in his or her lifetime) (19), alcohol consumption (patients who have previously drunk alcohol more than once per week), herbal teas with a putative biological effect consumption (patients who have previously drunk tea more than once per week), and weight loss (involuntary weight loss within 1 month), cancer stage; (2) Hematological Biomarkers: creatinine, hemoglobin, prealbumin, serum albumin, neutrophil to lymphocyte ratio (NLR), CRP: C-reactive Protein; (3) Anthropometric measures: body mass index (BMI), handgrip strength (HGS), mid-upper arm circumference (MUAC), triceps skinfold thickness (TSF), mid-arm muscle circumference (MAMC), calf circumference (CC), walking speed; (4) Pulmonary Function: peak expiratory flow (PEF), forced expiratory volume in 1s (FEV1) and vital capacity (VC); (5) Body composition: Intermuscular adipose tissue (IMAT), visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT); (6) Nutritional status scores: total muscle wasting score in PG-SGA (20), NRS-2002 score (21) and QLQ-C30 score (22). All of these variables (anthropometry and pulmonary function, etc.) were measured by clinicians who were uniformly trained to ensure reproducibility. Relevant data is recorded and stored in an electronic database within 1 week of admission.

Special parameters are measured as follows: (1) Handgrip strength (kg): the patient stands upright with the feet naturally apart and the non-dominant hand grip strength is measured using an electronic grip strength device (EH101; CAMRY). A total of 3 sets are tested, with a 1 min rest after each set, and values are taken to an accuracy of 0.1 kg; (2) MUAC (cm): the physician measures the distance between the surface of the scapula on the dorsal side of the non-dominant arm and the eminence of the elbow, marks the midpoint, asks the patient to drape the upper limb relaxed to the side of the body, wraps the tape measure around the midpoint of the upper arm and ties it tightly, and takes the value to 0.1 cm; (3) TSF (mm): the skin and subcutaneous tissue are pinched up with the thumb and index finger of the left hand at a point 1 cm above the midpoint of the dorsal aspect of the upper arm (from the crest of the shoulder to the midpoint of the ulnar eminence), with the skin fold parallel to the longitudinal axis of the upper arm; the thickness of the skin fold at the midpoint is determined within 3 seconds by measuring the physician with a skin-fold thickness gauge in the right hand, to an accuracy of 0.1 mm; (4) MAMC (cm) = MUAC (cm) − 0.314 * TSF (mm); (5) CC (cm): the patient is seated with the calf at a 90 degree angle to the seat and the left leg is selected for measurement. After exposing the calf, the physician places a tape measure around the thickest part of the calf to measure the circumference and takes the value to 0.1 cm; (6) Walking speed (m/s): the patient walks at the start line at normal speed and the time recorded is from the first foot moving to the first foot over the 6 m finish line. All the above parameters are measured three times, the maximum value is recorded for the step speed and the average value for the other parameters. At the same time, Supplementary Table 1 shows how the total
muscle wasting score in PG-SGA is assessed: the score with the highest number of occurrences of the “Muscle Loss Assessment” is counted as the total score for this item. For example, four of the seven muscle scores are 2 and three are 3, giving an overall score of “2.” In our study, the total muscle wasting score in PG-SGA included an assessment of muscle consumption in seven areas: temporalis in the temporal region, deltoid in the clavicular region, deltoid in the shoulder region, interosseous in the hand region, latissimus dorsi, rhomboid and deltoid in the scapular region, quadriceps in the thigh region and gastrocnemius in the calf region.

SMD, SMI and other body composition parameters

Body composition was measured by diagnostic non-enhanced CT scanning (Somtom Definition Flash, Siemens AG, Erlangen, Germany) prior to radical surgery. Body composition was measured by clinicians who were uniformly trained. Cross-sectional CT images of the third lumbar vertebra (L3) are closely correlated with whole-body adipose and muscle tissue in both cancer patients and healthy populations (23), and it is the de facto gold standard for measuring body composition.
TABLE 1 Baseline characteristics of colorectal patients in the two centers*.  

| Characteristics                        | Training cohort, n = 1,005 | External validation cohort, n = 632 |
|----------------------------------------|----------------------------|------------------------------------|
|                                        | Overall (n = 435) | Male (n = 570) | P value | Overall (n = 270) | Male (n = 362) | P value |
| Demographics                           |                           |                       |         |                |               |         |
| Age                                    | 59.7 ± 10.3              | 60.3 ± 10.1           | <0.001  | 54.4 ± 10.1    | 53.9 ± 10.2   | 0.226   |
| Diabetes, n (%)                        | 177(17.6)                | 194(34.1)             |         | 78(12.3)       | 35(12.9)      | 0.682   |
| Alcohol, n (%)                         | 165(16.4)                | 165(16.4)             | <0.001  | 86(13.6)       | 8(2.9)        | <0.001  |
| Smoking history, n (%)                 | 222(22.0)                | 222(22.0)             | <0.001  | 121(19.1)      | 186(6.6)      | <0.001  |
| Tea drinking, n (%)                    | 98(9.7)                  | 79(13.9)              | 0.761   | 72(11.3)       | 30(11.1)      | 0.848   |
| Weight loss, n (%)                     | 0.106                    |                       | 0.192   |                |               |         |
| Stable                                 | 530(52.7)                | 240(55.2)             |         | 492(77.8)      | 204(32.3)     | 0.965   |
| 0-4.9%                                 | 354(35.2)                | 201(35.3)             |         | 124(19.6)      | 61(9.7)       | 0.637   |
| ≥5%                                    | 121(12.1)                | 79(13.9)              |         | 16(2.6)        | 5(0.8)        | 0.113   |
| Cancer stage, n (%)                    |                          |                       | <0.001  |                |               |         |
| I                                      | 154(15.3)                | 86(15.1)              |         | 248(39.2)      | 106(16.8)     | 142(39.2)|
| II                                     | 292(29.1)                | 134(23.5)             |         | 188(29.7)      | 79(12.5)      | 109(17.2)|
| III                                    | 559(55.6)                | 350(61.4)             |         | 196(31.1)      | 85(13.4)      | 111(30.6)|
| Hematological biomarkers               |                           |                       |         |                |               |         |
| Creatinine, mg/dl                      | 65.1 ± 17.7              | 61.1 ± 15.8           | <0.001  | 76.2 ± 37.8    | 71.1 ± 49.4   | 0.046   |
| Hemoglobin, g/L                        | 130.3 ± 19.2             | 131.4 ± 19.5          | 0.041   | 130.7 ± 23.4   | 124.9 ± 20.6  | <0.001  |
| Prealbumin, mg/L                       | 258.2 ± 55.2             | 256.7 ± 55.4          | 0.318   | 264.9 ± 51.5   | 263.4 ± 48.3  | 0.536   |
| Albumin, g/L                           | 44.6 ± 6.3               | 44.3 ± 6.3            | 0.157   | 43.3 ± 5.2     | 43.5 ± 5.3    | 0.330   |
| NLR                                     | 3.1 ± 2.1                | 3.2 ± 2.2             | 0.234   | 2.5 ± 1.6      | 2.3 ± 1.2     | 0.031   |
| CRP                                     | 0.885                    |                       | 0.492   |                |               |         |
| ≥10                                    | 836(83.2)                | 361(80.0)             |         | 519(82.1)      | 329(81.2)     | 0.252   |
| >10                                    | 160(16.8)                | 74(17.0)              |         | 113(17.9)      | 68(18.8)      | 0.167   |
| Human body measurement                 |                           |                       |         |                |               |         |
| BMI, kg/m²                              | 21.8 ± 4.0               | 21.9 ± 4.1            | 0.708   | 23.7 ± 3.6     | 23.5 ± 3.4    | 0.959   |
| Handgrip strength, kg                  | 22.2 ± 7.1               | 23.4 ± 3.8            | <0.001  | 25.4 ± 3.6     | 24.5 ± 3.5    | <0.001  |
| MUAC, cm                               | 23.2 ± 3.6               | 23.4 ± 3.8            | 0.097   | 25.4 ± 3.6     | 24.5 ± 3.5    | <0.001  |
| TSE, mm                                | 20.6 ± 6.9               | 18.9 ± 6.8            | 0.042   | 20.9 ± 7.6     | 19.9 ± 7.4    | 0.001   |
| MAMC, cm                               | 16.7 ± 3.9               | 17.0 ± 4.1            | 0.007   | 18.8 ± 4.2     | 17.5 ± 4.0    | <0.001  |
| CC, cm                                 | 30.9 ± 4.7               | 32.0 ± 4.4            | <0.001  | 32.5 ± 4.4     | 31.9 ± 4.4    | 0.013   |
| Walking speed m/s                      | 1.0 ± 0.6                | 1.1 ± 0.6             | 0.137   | 1.1 ± 0.7      | 1.0 ± 0.6     | 0.570   |
| Pulmonary function                     |                           |                       |         |                |               |         |
| PEF, L/s                               | 4.5 ± 1.3                | 4.7 ± 1.2             | <0.001  | 4.3 ± 1.3      | 4.2 ± 1.3     | 0.044   |
| FEVI, L                                | 2.0 ± 0.5                | 2.2 ± 0.5             | <0.001  | 1.9 ± 0.4      | 1.8 ± 0.4     | <0.001  |
| VC, L                                  | 2.7 ± 0.7                | 2.8 ± 0.6             | 0.232   | 2.6 ± 0.6      | 2.4 ± 0.6     | <0.001  |
| Body composition                       |                           |                       |         |                |               |         |
| IMAT, cm²                               | 15.9 ± 6.8               | 15.7 ± 6.7            | 0.671   | 14.7 ± 6.4     | 15.2 ± 6.2    | 0.077   |
| VAT, cm²                               | 131.9 ± 54.4             | 149.8 ± 50.5          | <0.001  | 133.5 ± 50.9   | 115.4 ± 46.1  | <0.001  |
| SAT, cm²                               | 148.7 ± 48.3             | 131.7 ± 44.9          | <0.001  | 147.3 ± 46.2   | 165.2 ± 42.9  | <0.001  |
| SMD, HU                                 | 36.0 ± 6.1               | 35.6 ± 6.2            | <0.001  | 36.0 ± 6.3     | 35.6 ± 6.4    | 0.137   |
| SMI, cm²/m²                             | 44.4 ± 11.8              | 46.5 ± 11.1           | <0.001  | 44.3 ± 11.4    | 40.5 ± 10.9   | <0.001  |
| LSMI, n (%)                             | 332(33.0)                | 196(34.3)             | 0.297   | 195(30.8)      | 81(30.0)      | 0.688   |
| LSNII, n (%)                            | 416(41.3)                | 241(42.2)             | 0.513   | 231(36.5)      | 99(36.6)      | 0.958   |

(Continued)
(muscle and adipose compartments) in oncology (24). The muscles at the L3 level, including the rectus abdominis, internal oblique, external oblique, transverse abdominis, psoas major, psoas square and erector spinae muscles. We selected a single image of the third lumbar vertebra (L3) for body composition quantification, including all skeletal muscle mass, visceral adipose tissue (VAT), intermuscular adipose tissue (IMAT) and subcutaneous adipose tissue (SAT). For adipose tissue, standard CT values range from −30 Hounsfield Units for IMAT to −190 to −30 Hounsfield Units for VAT; for muscle tissue, the standard CT values range from −29 to 150 Hounsfield Units (HU) (23, 25). We used SliceOmatic Software version 5.0 (TomoVision) to measure tissue area, total abdominal muscle area (TAMA) measured at L3 divided by the square of height as SMI (cm²/m²), and the mean radiation attenuation value of the muscle group measured at L3 as SMD (HU).

### Definitions of malnutrition and sarcopenia

Malnutrition is defined according to the GLIM criteria, which consists of two modules: phenotypic criteria and etiological criteria. There are 2 possible etiological criteria: (1) reduced food intake or digestive and absorptive function; (2) inflammation or disease burden; And 3 possible phenotypic criteria: (1) weight loss; (2) low BMI; and (3) reduced muscle mass. The NRS2002 was used as the initial screening step as part of GLIM and included into the all patients’ routine preoperative assessment. Patients at risk of malnutrition (NRS2002 ≥ 3) were diagnosed as malnourished if they met at least one etiological criterion and one phenotypic criterion at the same time. With regard to the etiological criteria of inflammation, recruitment and activation of inflammatory cells can promote tumor progression, and tumor cells in turn can secrete chemokines, pro-inflammatory cytokines and inflammatory enzymes (26). Therefore, all colorectal cancer patients were considered to have met the etiological criteria by virtue of their diagnosis In our study, we defined low BMI (kg/m²) using Asian criteria, with BMI < 20 for patients aged over 70 years and < 18.5 for those aged <70 years (13). Also, we used the validated value of LSMI to define muscle mass loss.

The diagnosis of sarcopenia is made up of two components: low muscle mass or low muscle quality and low grip strength according to the EWGSOP-2 Asian consensus (11). A diagnosis of sarcopenia is made when 2 criterias are met simultaneously. The cutoffpoints for low SMD is 32.5 HU in women and 35.5 HU in men (27). Low SMI cutoffpoints were ≤36.2 and ≤29.6 cm²/m² for men and women, respectively (28, 29). In addition, low grip strength is defined as <18 kg for women and <26 kg for men (30).

### Follow-up assessments

We followed up patients at the Fourth Hospital of Harbin Medical University by telephone or in hospital according to National Comprehensive Cancer Network (NCCN) follow-up principles (31). The follow-up visits included physical examination, biochemistry, CA19-9, CEA, abdominal and pelvic ultrasound, thoracoabdominal and pelvic CT or MRI and

---

**TABLE 1 (Continued)**

| Characteristics | Training cohort, n = 1,005 |  |  | External validation cohort, n = 632 |  |  |
|-----------------|----------------------------|---|---|-------------------------------------|---|---|
|                 | Overall (n = 1,005) | Female (n = 435) | Male (n = 570) | P-value | Overall (n = 632) | Female (n = 270) | Male (n = 362) | P-value |
| **Scores**      |                           |                           |                       |          |                           |                           |                       |          |
| Total muscle wasting score, n (%) | 0.091 |  |  | 0.824 |  |  |  |  |
| 0                | 337(33.5) | 133(39.6) | 204(35.8) | 345(54.6) | 150(55.6) | 195(53.8) |  |  |
| 1                | 207(20.6) | 100(23.0) | 107(18.8) | 98(15.5) | 38(14.1) | 60(16.5) |  |  |
| 2                | 251(25.0) | 102(23.4) | 149(26.1) | 100(15.8) | 42(15.5) | 58(16.0) |  |  |
| 3                | 210(20.9) | 100(23.0) | 110(19.3) | 89(14.1) | 40(14.8) | 49(7.7) |  |  |
| NRS-2002 score, n (%) | 0.892 |  |  | 0.475 |  |  |  |  |
| <3               | 613(61.0) | 264(60.7) | 349(61.2) | 538(85.1) | 233(86.3) | 305(84.3) |  |  |
| ≥3               | 392(39.0) | 171(39.3) | 221(38.8) | 94(14.9) | 37(14.1) | 57(15.7) |  |  |
| QLQ-C30 score   | 49.1 ± 14.1 | 50.4 ± 15.2 | 48.0 ± 13.1 | 0.192 | 50.6 ± 11.3 | 50.7 ± 11.0 | 50.5 ± 11.5 | 0.779 |

*Values are n (%) or means ± SDs. NLR, neutrophil to lymphocyte ratio; CRP, C-reactive Protein; BMI, body mass index; MUAC, mid-upper arm circumference; TSF, triceps skin fold; SMI, skeletal muscle index; LSMI, low skeletal muscle mass index; SMD, low skeletal muscle radiodensity; MAMC, mid-arm muscle circumference; CC, calf circumference; PEF, peak expiratory flow; FEV1, Forced Expiratory Volume In 1 s; VC, Vital Capacity; IMAT, Intramuscular adipose tissue; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; HU, Hounsfield unit; SMD, skeletal muscle radiodensity; SM I, skeletal muscle index; LSMD, low skeletal muscle radiodensity; NRS, nutritional risk screening; QLQ-C30, Quality of Life Questionnaire-Core 30. A chi-square test was used for categorical variables to assess differences between groups and Student’s t-test or Mann-Whitney U-test was used for continuous variables.
colonoscopy. Follow-up is every 3 months for 2 years after surgery and every 6 months for 3–5 years after surgery. The last follow-up was in March 2022. Overall survival is calculated from the first day after surgery to the time of death due to any cause.

**Statistical analysis**

Statistical analyses of all data were performed using SPSS statistics version 25.0 (IBM, Armonk, NY), R version 4.1.2 (R Project for Statistical Computing, Vienna, Austria), X-tile plots (Yale University School of Medicine, New Haven, Connecticut, USA) and MedCalc software version 20.10.6 (MedCalc, Mariakerke, Belgium). Continuous data were expressed as means ± SDs and compared using Student’s t-test. Categorical variables were expressed as frequencies (%) and compared using Pearson’s chi-square test or Fisher’s exact test. In the training cohort, logistic regression analysis was used to predict low SMD and low SMI, respectively. Significant preoperative factors were included in the multivariate logistic regression analysis. Risk factors that proved to be significant in the training cohort were used to create nomograms and the validity of the associated predictive factors was evaluated in the validation cohort. The utility of the developed model was also assessed by calibration curves, discrimination curve analysis (DCA) and area under the curve (AUC). The calibration and discrimination of the nomogram were assessed using AUC and calibration curves.

**Predictors associated with low SMD and low SMI**

A total of 31 hypothesized risk factors were included in this study. In the training cohort, multivariable logistic regression analysis showed that age, tumor-node-metastasis (TNM) stage, BMI, IMAT, walking speed, total muscle wasting score in PG-SGA and NRS2002 score were significantly associated with low SMD (p < 0.05; Table 2); age, NLR, BMI, PEF, handgrip strength, calf circumference, walking speed, total muscle wasting score in PG-SGA and NRS2002 score were significantly correlated with low SMI (p < 0.05; Table 3). We further found that patients with lower age, TNM stage, IMAT, total muscle wasting score in PG-SGA and NRS2002 score had a lower risk of LSMD, while patients with low BMI and low walking speed had a higher risk of LSMD. In addition, patients with lower BMI, PEF, handgrip strength, calf circumference, walking speed had a higher risk of LSMI. Notably, BMI was a strong predictor of low SMD and low SMI, with AUC values of 0.793 and 0.766 in the training cohort, respectively. The best cutpoint for BMI in stratifying LSMD was 18.5 kg/m², similar to the phenotypic criteria for low BMI in the GLIM criteria. As the total muscle wasting score in PG-SGA progressively increases from 0 to 3, the risk of low SMD and low SMI also progressively increases. In terms of body composition parameters, patients with an IMAT >18.6 cm² have a higher risk of low SMD.

**Nomograms construction, validation and clinical performance**

Based on the low SMD rate in the training cohort, we constructed a nomogram using seven independent predictors including age, TNM stage, BMI, IMAT, walking speed, total muscle wasting score in PG-SGA and NRS2002 score (Figure 2) after multivariate logistic regression analysis. Similarly, the predictive nomogram containing all the independent risk factors for low SMI in the training cohort is shown in Figure 3. In the validation cohort, we included the above risk factors associated with low SMD and low SMI to demonstrate the validity of the identified risk factors and nomogram. The calibration curve was close to 45 degrees, which indicated that the low SMD and low SMI probabilities predicted by the nomogram in both the training and validation cohorts were in good agreement with the actual probabilities (Figure 4). The DCA curves showed good clinical performance of the two models in diagnosing low SMD and low SMI in both clinical centers (Supplementary Figure 1).
TABLE 2 Univariate and multivariate logistic regression analyses of the risk factors associated with low SMD in the training cohort*.

| Characteristics          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | OR                  | P value (95% CI)       | OR                  | P value (95% CI)       |
| Demographics             |                     |                       |                     |                       |
| Sex                      | 0.87(0.67,1.13)     | 0.297                 | 1.03(1.02,1.05)     | <0.001                |
| Age                      | 1.06(1.04,1.07)     | <0.001                | <0.001              |                       |
| Diabetes, n (%)          | 0.87(0.61,1.23)     | 0.431                 | 0.74(0.59,0.94)     | 0.026                 |
| Alcohol, n (%)           | 1.05(0.74,1.29)     | 0.287                 | 0.97(0.71,1.33)     | 0.036                 |
| Smoking history, n (%)   | 1.04(0.76,1.43)     | 0.788                 | 0.78(0.60,1.00)     | <0.001                |
| Tea drinking, n (%)      | 1.52(1.00,2.33)     | 0.052                 | 1.03(0.71,1.52)     | 0.001                 |
| Weight loss, n (%)       | <0.001              | 0.363                 | <0.001              |                       |
| Stable                   | Reference           | Reference             | Reference           |                       |
| 0–4.9%                   | 1.36(1.01,1.82)     | 0.311                 | 1.31(0.87,1.97)     | 0.297                 |
| ≥5%                      | 3.29(2.04,9.55)     | 0.049                 | 0.94(0.53,1.69)     | 0.893                 |
| Cancer stage, n (%)      | <0.001              | <0.001                | <0.001              |                       |
| I                        | Reference           | Reference             | Reference           |                       |
| II                       | 2.68(1.56,4.62)     | 0.001                 | 2.84(1.41,5.72)     | 0.001                 |
| III                      | 5.08(3.05,8.45)     | 0.001                 | 4.36(2.28,8.33)     | 0.001                 |
| Hematological biomarkers |                     |                       |                     |                       |
| Creatinine, mg/dl        | 1.01(1.00,1.01)     | 0.099                 | 1.01(0.99,1.05)     | 0.054                 |
| Hemoglobin, g/L          | 1.01(1.00,1.01)     | 0.082                 | 1.00(0.99,1.01)     | 0.541                 |
| Prealbumin, mg/L         | 1.00(0.99,1.00)     | 0.994                 | 1.00(0.99,1.00)     | 0.994                 |
| Albumin, g/L             | 0.99(0.97,1.01)     | 0.516                 | 0.99(0.97,1.01)     | 0.516                 |
| NLR                      | 1.27(1.17,1.37)     | <0.001                | 1.07(0.97,1.18)     | 0.176                 |
| CRP                      | 1.05(0.90,1.22)     | 0.080                 | 1.05(0.90,1.22)     | 0.080                 |
| Anthropometric measurements |                   |                       |                     |                       |
| BMI, kg/m²               | 0.74(0.71,0.78)     | <0.001                | 0.92(0.87,0.97)     | 0.002                 |
| Handgrip strength, kg    | 0.99(0.97,1.01)     | 0.223                 | 0.99(0.97,1.01)     | 0.223                 |
| MUAC, cm                 | 1.00(0.96,1.04)     | 0.994                 | 1.00(0.96,1.04)     | 0.994                 |
| TSE, mm                  | 1.00(0.98,1.02)     | 0.800                 | 1.00(0.98,1.02)     | 0.800                 |
| MAMC, cm                 | 1.00(0.96,1.03)     | 0.893                 | 1.00(0.96,1.03)     | 0.893                 |
| CC, cm                   | 1.01(0.98,1.04)     | 0.428                 | 1.01(0.98,1.04)     | 0.428                 |
| Walking speed, m/s       | 0.30(0.24,0.39)     | <0.001                | 0.40(0.29,0.54)     | <0.001                |
| Pulmonary function       |                     |                       |                     |                       |
| PEF, L/s                 | 1.04(0.94,1.15)     | 0.459                 | 1.04(0.94,1.15)     | 0.459                 |
| FEV1, L                  | 0.89(0.67,1.28)     | 0.432                 | 0.89(0.67,1.28)     | 0.432                 |
| VC, L                    | 0.83(0.68,1.02)     | 0.071                 | 0.83(0.68,1.02)     | 0.071                 |
| Body composition         |                     |                       |                     |                       |
| IMAT, cm²                | 1.06(1.04,1.09)     | <0.001                | 1.10(1.07,1.14)     | <0.001                |
| VAT, cm²                 | 1.00(0.99,1.01)     | 0.676                 | 1.00(0.99,1.01)     | 0.676                 |
| SAT, cm²                 | 0.99(0.99,1.00)     | 0.268                 | 0.99(0.99,1.00)     | 0.268                 |
| VAT/SAT                  | 1.11(0.91,1.35)     | 0.299                 | 1.11(0.91,1.35)     | 0.299                 |
| Scores                   |                       |                       |                     |                       |
| Total muscle wasting score, n (%) | 4.50(2.76,7.35)  | 3.77(2.10,6.76)        | 4.50(2.76,7.35)  | 3.77(2.10,6.76)        |

(Continued)

To compare the predictive performance of the nomogram with other risk factors, we calculated area under the curve (AUC) (Supplementary Table 2) and plotted the ROC curves for the associated risk factors and nomograms (Figure 5). The AUC values for low SMD and low SMI were 0.890 (95% CI, 0.875 to 0.908) and 0.916 (95% CI, 0.897 to 0.933) in the training cohort and 0.859 (95% CI, 0.831 to 0.886) and 0.843 (95% CI, 0.813 to 0.871) in the validation cohort, respectively.

Survival analyses

The Kaplan-Meier analysis showed that the 3- and 5-year overall survival rates were 83.2 and 88.5% in the training cohort. A total of 31 preoperative factors were included in the univariate and the multivariate Cox regression analyses. Multivariate Cox proportional risk analysis showed that TNM stage, low SMD and low SMI were significantly associated with OS (p < 0.01; Supplementary Table 3). Low SMD [hazard ratio (HR) 2.11, p < 0.0001] indicates that patients with LSMI have a 1.31-fold increased risk of death compared to those without LSMI. Low SMI [hazard ratio (HR) 2.31, p < 0.0001] indicates that patients with LSMI have a 1.11-fold increased risk of death compared to those without LSMI. Relevant patients were screened according to the criteria of malnutrition and sarcopenia. We found that the prevalence of malnutrition was 33.8% (n = 340) and sarcopenia was 34.0% (n = 342).

As observed in the Kaplan-Meier curve, patients with low SMD (Figure 6A), low SMI (Figure 6B), malnutrition (Figure 6C), or sarcopenia (Figure 6D) had worse survival rates.
TABLE 3 Univariate and multivariate logistic regression analyses of the risk factors associated with low SMI in the training cohort.

| Characteristics          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                         | OR (95% CI)         | P value               | OR (95% CI)         | P value               |
| **Demographics**         |                     |                       |                      |                       |
| Sex                      | 0.92 (0.71, 1.18)   | 0.513                 |                       |                       |
| Age                      | 1.09 (1.08, 1.11)   | <0.001                | 1.07 (1.05, 1.10)    | <0.001                |
| Diabetes, n (%)          | 0.82 (0.58, 1.14)   | 0.222                 |                       |                       |
| Alcohol, n (%)           | 0.93 (0.66, 1.31)   | 0.691                 |                       |                       |
| Smoking history, n (%)   | 1.05 (0.78, 1.42)   | 0.745                 |                       |                       |
| Tea drinking, n (%)      | 1.23 (0.81, 1.87)   | 0.339                 |                       |                       |
| Weight loss, n (%)       | <0.001              | 0.369                 |                       |                       |
| Stable                   | Reference           | Reference             |                       |                       |
| 0–4.9%                  | 1.35 (1.03, 1.78)   | 1.12 (0.79, 1.82)     |                       |                       |
| ≥5%                     | 2.61 (1.74, 3.91)   | 0.76 (0.39, 1.45)     |                       |                       |
| Cancer stage, n (%)      | <0.001              | 0.125                 |                       |                       |
| I                       | Reference           | Reference             |                       |                       |
| II                      | 0.94 (0.62, 1.41)   | 0.66 (0.35, 1.22)     |                       |                       |
| III                     | 1.83 (1.26, 2.66)   | 1.06 (0.60, 1.85)     |                       |                       |
| **Hematological biomarkers** |                     |                       |                      |                       |
| Creatinine, mg/dl        | 1.00 (0.99, 1.01)   | 0.988                 |                       |                       |
| Hemoglobin, g/L          | 1.00 (1.00, 1.01)   | 0.400                 |                       |                       |
| Prealbumin, mg/L         | 0.99 (0.99, 1.01)   | 0.679                 |                       |                       |
| Albumin, g/L             | 1.02 (1.00, 1.04)   | 0.071                 |                       |                       |
| NLR                      | 1.55 (1.41, 1.70)   | <0.001                | 1.24 (1.12, 1.37)    | <0.001                |
| CRP                      | 0.99 (0.99, 1.00)   | 0.550                 |                       |                       |
| **Anthropometric measurements** |                     |                       |                      |                       |
| BMI, kg/m²               | 0.78 (0.75, 0.82)   | <0.001                | 0.92 (0.87, 0.97)    | 0.003                 |
| Handgrip strength, kg    | 0.91 (0.89, 0.93)   | <0.001                | 0.93 (0.90, 0.96)    | <0.001                |
| MUAC, cm                 | 0.99 (0.95, 1.02)   | 0.473                 |                       |                       |
| TSE, mm                  | 0.99 (0.98, 1.01)   | 0.461                 |                       |                       |
| MAMC, cm                 | 1.00 (0.96, 1.03)   | 0.797                 |                       |                       |
| CC, cm                   | 0.89 (0.87, 0.92)   | <0.001                | 0.91 (0.87, 0.95)    | <0.001                |
| Walking speed m/s        | 0.34 (0.27, 0.42)   | <0.001                | 0.43 (0.32, 0.58)    | <0.001                |
| **Pulmonary function**   |                     |                       |                      |                       |
| PEF, L/s                 | 0.64 (0.57, 0.71)   | <0.001                | 0.61 (0.53, 0.71)    | <0.001                |
| FEV₁, L                  | 1.15 (0.87, 1.50)   | 0.327                 |                       |                       |
| VC, L                    | 0.96 (0.79, 1.16)   | 0.679                 |                       |                       |
| **Body composition**     |                     |                       |                      |                       |
| IMAT, cm²                | 0.99 (0.97, 1.01)   | 0.297                 |                       |                       |
| VAT, cm²                 | 1.00 (1.00, 1.01)   | 0.099                 |                       |                       |
| SAT, cm²                 | 0.99 (0.99, 1.00)   | 0.596                 |                       |                       |
| VAT/SAT                  | 1.04 (0.86, 1.26)   | 0.707                 |                       |                       |
| **Scores**               |                      |                       |                      |                       |
| Total muscle wasting score, n (%) | <0.001        | <0.001                |                       |                       |

(Continued)

TABLE 3 (Continued) Univariate and multivariate logistic regression analyses of the risk factors associated with low SMI in the training cohort.

| Characteristics          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                         | OR (95% CI)         | P value               | OR (95% CI)         | P value               |
| **NRS-2002 score, n (%)** |                     |                       |                      |                       |
| <3                      | Reference           | Reference             |                       |                       |
| ≥3                      | 6.38 (4.82, 8.45)   | 2.56 (1.56, 4.22)     |                       |                       |
| QLQ-C30 score           | 1.01 (1.00, 1.02)   | 0.003                 | 1.01 (0.99, 1.02)    | 0.336                 |

*Data are analyzed by univariate and multivariate logistic regression analysis. Risk factors with significance in univariate analysis were included in the multivariate analysis (p < 0.05): NLR, neutrophil-lymphocyte ratio; CRP, C-reactive Protein; BMI, body mass index; MUAC, mid-upper arm circumference; TSE, triceps skinfold thickness; MAMC, mid-arm muscle circumference; CC, Calf circumference; PEF, Peak expiratory flow; FEV₁, Forced Expiratory Volume In 1s; VC, Vital Capacity; IMAT, intermuscular adipose tissue; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; HU, Hounsfield unit; SMD, skeletal muscle radiodensity; LSMD, low skeletal muscle mass index; LSMD, low skeletal muscle radiodensity; NRS, nutritional risk screening; QLQ-C30, Quality of Life Questionnaire-Core 30.

compared to normal patients. We used X-tile to determine that the cut-off value of NLR is 3.5. When only NLR was considered, the KM curve and log-rank test results indicated a significant difference in the distribution of overall survival (OS) between nonmetastatic CRC patients with high NLR (≥3.5) and low NLR (<3.5). Neutrophil-lymphocyte ratio (NLR) is a measure of systemic inflammation, and NLR ≥3.5 meets the criteria of moderate to high inflammation. Our study found that patients with NLR ≥3.5 and malnutrition had a nearly 1-fold increased risk of death compared to patients with NLR < 3.5 and malnutrition (log-rank P < 0.001) (Figure 6E). In addition, a similar presentation was found in patients with sarcopenia (log-rank P < 0.001) (Figure 6F). The study suggests that moderate-to-severe inflammatory status may influence survival in nonmetastatic CRC patients with malnutrition or sarcopenia.

**Discussion**

To our knowledge, this is the first study to assess the predictive ability of total muscle wasting score in PG-SGA and intermuscular adipose tissue (IMAT) for CT-derived muscle radiodensity and muscle mass, and the largest study to explore demographic and medical characteristics associated with low SMD and low SMI in colorectal cancer patients based on a Chinese population. We found that as the total muscle wasting score in PG-SGA increased from 0 to 3, the risk of low SMD and low SMI also increased, which may be the most direct indicator for clinical assessment of muscle abnormalities. Intermuscular adipose tissue (IMAT), a body composition...
FIGURE 2
The nomogram for predicting low SMD based on the training cohort (n = 1,005).

FIGURE 3
The nomogram for predicting low SMI based on the training cohort (n = 1,005).
parameter, better predicted low SMD, but did not correlate clearly with low SMI. When IMAT > 18.6 cm², the patient’s low SMD rate increased considerably.

To ensure a more comprehensive determination of risk factors for low SMD and low SMI, we collected a total of 31 preoperative risk factors based on six aspects: demographic characteristics, hematological parameters, anthropometry, lung function, body composition parameters and nutritional status score. Our study showed that age, TNM stage, BMI, IMAT, walking speed, total muscle wasting score in PG-SGA and NRS 2002 score were independent factors for low SMD; age, NLR, BMI, PEF, handgrip strength, calf circumference, walking speed, total muscle wasting score in PG-SGA and NRS 2002 score were independent factors for low SMI. The diagnostic nomogram consisting of these preoperative factors successfully predicted low SMD and low SMI in the training cohort and validation cohort with good discrimination and accuracy. It has the potential to help us to identify patients with muscle abnormalities early and to intervene in the early treatment of these patients.

In survival analyses, we found that patients with low SMD, low SMI, malnutrition or sarcopenia had a poorer prognosis. Furthermore, the co-occurrence of malnutrition or sarcopenia and inflammation were associated with a high risk of death, which is consistent with previous results on exploring the coexistence of NLR and sarcopenia in small cell lung cancer (33). One possible explanation is that high NLR is due to a relatively increased neutrophil count, suggesting that the inflammatory state alters the tumor micro-environment, impairing the patient’s immune response to malignancy and thereby promoting tumor progression and metastasis (34); it could also be due to a relatively depleted lymphocyte count, which can act as tumor-promoting leucocytes by producing IL-10 and TGF-β, thereby inducing matrix metalloproteinases and regulatory T-cell pathways in the tumor micro-environment (35). NLR, as a marker of systemic inflammation, is not only
associated with elevated concentrations of various cytokines in the colorectal cancer circulation (36), but also an enhancer of muscle destruction. For example, a state of systemic inflammation can increase tumor necrosis factor production by tumor or surrounding cells, thereby inhibiting skeletal muscle cell differentiation and promoting muscle atrophy (37, 38).

IMAT is one of the reported measures of myosteatosis (39). Myosteatosis can be understood as a pathological accumulation of fat in muscle, associated with reduced mitochondrial lipid oxidation, insulin resistance and reduced muscle activity (23). Our study showed a direct correlation between IMAT and low SMD, which can be interpreted as an indication that excessive intermuscular infiltration of fat leads to reduced skeletal muscle function as well as reduced CT values of skeletal muscle over a cross-sectional area. We hypothesize that SMD is more influenced by metabolic factors and that high circulating free fatty acid concentrations are thought to impair intermuscular fat metabolism and mitochondrial oxidation, thus leading to fat accumulation into muscle (40). Future studies will be necessary to investigate the exact association between decreased SMD and metabolic disturbances in patients with colorectal cancer.

Muscle atrophy and senescence are important signs of body aging. Increasing age is often accompanied by accelerated muscle loss (41) and redistribution of adipose tissue between or within skeletal muscles (42). The association between old age and muscle abnormalities has also been observed in...
nonmalignant diseases (43) and other cancers (44). In our training cohort of patients aged ≥60, 62.6% had low SMI and 44.1% had low SMD. Studies have shown that decreases in age-related hormones (e.g., insulin, growth hormone, insulin-like growth factor, testosterone) are strongly associated with the development of sarcopenia (45). As the rapid increase in the world's aging population and elderly cancer patients, the mechanisms of interaction between aging and intramuscular (distributed within muscle tissue) and intermuscular (localized between muscle groups) fat penetration must be explored, and the prevention and treatment of muscle abnormalities has profound implications for improving the quality of life of older people and reducing the burden of diseases such as sarcopenia on society.

Anthropometric (AM) measures such as BMI, walking speed, grip strength (HGS) and calf circumference (CC), MUAC, mid-upper arm circumference (MUAC), triceps fold thickness (TSF), mid-arm muscle circumference (MAMC) may be inexpensive, non-invasive, reproducible, extensive, rapid and simple alternatives to assess sarcopenia, malnutrition, low SMD or low SMI in cancer patients (46). Our findings regarding the association of grip strength (47), calf circumference (48), BMI (49), and walking speed (50) with low muscle mass are consistent with previous studies. After middle age, HGS declines with age at a rate of approximately 1% per year (51). The European guidelines for sarcopenia (11) suggest that grip strength, a supportive measure of sarcopenia, has a significant impact on clinical prognosis in cancer patients. Interestingly, we found that HGS was associated with low SMI but not low SMD, and it is possible that there is no linear association between muscle radiodensity and muscle strength. TSF, one of the components of malnutrition screening, is often used to assess free fat mass. However, we did not find a direct association between TSF and low SMD or low SMI. The study highlights the importance of considering anthropometric parameters simultaneously to provide additional information when assessing risk or planning intervention strategies for these patients.

Sarcopenia not only affects the extremities, but also causes a loss of strength and mass in a wider range of skeletal muscles, including respiratory muscles (e.g., the diaphragm) (52). The
decline in respiratory strength associated with aging can also be termed “respiratory sarcopenia” (53). In clinical work, patients often routinely undergo preoperative pulmonary function tests as an important tool to determine the risk of anesthesia. However, few have explored the correlation between pulmonary function indicators and muscle radiodensity and muscle mass. Our study included pulmonary function parameters such as PEF and FEV1, and the results showed a clear association between PEF and low SMI in patients with non-metastatic colorectal cancer compared to FEV1. The reason for this may be that FEV1 is largely confounded by airway obstruction. In contrast, PEF, determined by the strength of the respiratory muscles, is obtained during early expiration prior to airway obstruction (54). Thus, PEF is unaffected by airway obstruction.

Overall, the nomogram allows us to assess the probability of patients developing LSMI and LSMD based on the scores of each relevant factor, so that we can carry out nutritional interventions for such risk groups, which is of great importance for clinical work. However, the current study has some limitations worth noting. First, the mean BMI in our study was low and may be more representative of the Chinese population than other populations. Further studies are needed to validate our findings in overweight or class I-III obese populations. Secondly, selection bias may affect the generalisability of the results as this study only included patients with curable colorectal cancer. Therefore, the lack of data on patients with metastatic colorectal cancer may limit the scope of its application. Third, even with relatively large cohorts, more data is needed to determine cut-off values for these predictors so that clinicians could be given definitive guidance in determining low SMD and low SMI. Finally, because it is a cross-sectional study and it could not determine the causality between low SMI/SMD and enrolled factors, which should be deemed as one of the limitations in the present research.

Conclusion

In conclusion, our study is the first to demonstrate the predictive value of total muscle wasting score in PG-SGA and intermuscular adipose tissue (IMAT) for muscle abnormalities. The study also shows that demographic characteristics combined with nutrition-related medical parameters can provide a more comprehensive risk assessment of low SMD and low SMI. Finally, because it is a cross-sectional study and it could not determine the causality between low SMI/SMD and enrolled factors, which should be deemed as one of the limitations in the present research.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

Ethics statement

This study was reviewed and approved by the Research Ethics Committee of the Second Affiliated Hospital of Harbin Medical University and the Fourth Affiliated Hospital of Harbin Medical University, China. Patients/participants provided written informed consent to participate in this study.

Author contributions

YaW designed the study, contributed to project conception, performed the statistical analysis, and wrote the paper. YuW and GL contributed to project conception, data analysis, interpretation, editing, and critical review. HZ and HY contributed to study design, interpretation, and editing. JX and ZW conducted the literature search and collected the data. XJ and GY collected the data and contributed to analysis and editing. YL, CW, and HX contributed to interpretation and editing. HS and GW contributed to editing and critical review. All authors read and approved the final version submitted.

Funding

This project was supported by the Natural Science Foundation of Heilongjiang Province, China-Joint Guidance Project (Grant No. LH2020H066).

Acknowledgments

The authors would thank all the patients for their commitment and patience during the study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.967902/full#supplementary-material

References

1. Frontera WR, Ochala J. Skeletal muscle: a brief review of structure and function. Calcif Tissue Int. (2015) 96:183–95. doi: 10.1007/s00223-014-9915-y
2. Larsson L, Degnes H, Li M, Saviati L, Lee YJ, Thompson W, et al. Sarcopenia: aging-related loss of muscle mass and function. Physiol Rev. (2019) 99:427–511. doi: 10.1152/physrev.00061.2017
3. Kazemi-Bajestani SM, Mazarak VC, Baracos V. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol. (2016) 54:2–10. doi: 10.1016/j.semcdb.2015.09.001
4. Barret M, Antonius S, Dalban C, Malla D, Mansourbalht T, Zaanan A, et al. Sarcopenia is linked to treatment outcomes in patients with metastatic colorectal cancer. Nutr Cancer. (2014) 66:583–9. doi: 10.1080/01635581.2014.894103
5. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia is a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. (2009) 15:2920–6. doi: 10.1158/1078-0432.CCR-08-2242
6. Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. (2016) 75:188–98. doi: 10.1017/S0033589415004279
7. Sung H, Ferlay J, Siegel RL, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660
8. Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Inst. (2022) 5:38. doi: 10.1093/jnci/djja311
9. Maleziass G, Carrie AC, Athanasious T, Johna N, Anyanete N, Glynne-Jones R, et al. Influence of body composition profile on outcomes following colorectal surgery. Br J Surg. (2016) 103:572–80. doi: 10.1002/bjs.10075
10. Pedziwiatr M, Pierskalska M, Major P, Grochowska A, Matlokh T, Przezcek K, et al. Laparoscopic colorectal cancer surgery combined with enhanced recovery after surgery protocol (ERAS) reduces the negative impact of sarcopenia on short-term outcomes. Eur J Surg Oncol. (2016) 42:779–87. doi: 10.1016/j.ejso.2016.03.037
11. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. (2019) 48:601. doi: 10.1093/ageing/azz046
12. Muresan BT, Sanchez Juan C, Artero A, Hernandez Machacanoes A, Almendros-Blanco P, Montero A, et al. Measurement of body composition in cancer patients using CT planning scan at the third lumbar vertebra. Nutr Hosp. (2019) 36:1307–14. doi: 10.20960/nh.2435
13. Cederholm T, Jensen GL, Correia M, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. (2019) 38:1–9. doi: 10.1016/j.clnu.2018.08.002
14. De Groot LM, Lee G, Ackerie A, van der Meij BS. Malnutrition Screening and Assessment in the Cancer Care Ambulatory Setting: Mortality Predictability and Validity of the Patient-Generated Subjective Global Assessment Short form (PG-SGA SF) and the GLIM Criteria. Nutrients. (2020) 12:2287. doi: 10.3390/nu12082287
15. Jager-Wittemaar H, Ottery FD. Assessing nutritional status in cancer: role of the Patient-Generated Subjective Global Assessment. Curr Opin Clin Nutr Metab Care. (2017) 20:322–9. doi: 10.1097/MCO.0000000000000389
16. Erickson N, Strock LJ, Kolm A, Norman K, Fey T, Schiffer V, et al. Tri-country translation, cultural adaptation, and validity confirmation of the Scored Patient-generated subjective global assessment. Support Care Cancer. (2019) 27:3499–507. doi: 10.1007/s00520-019-4637-3
17. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. (2013) 31:1539–47. doi: 10.1200/JCO.2012.45.2722
18. Cospedes Feliciano EM, Avrutin E, Caan BJ, Boroian A, Mourtzakis A. Sarcopenia: Screening for low muscularity in colorectal cancer patients - a valid, clinic-friendly approach that predicts mortality. J Cachexia Sarcopenia Muscle. (2018) 9:898–908. doi: 10.1002/jcsm.12317
19. Foxon F, Sylla AS. Electronic cigarettes, nicotine use trends and use initiation ages among US adolescents from 1999 to 2018. Addiction. (2020) 115:2269–78. doi: 10.1111/add.15099
20. Bauer J, Capra S, Ferguson M. Use of the scored patient-generated subjective global assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. (2002) 56:779–83. doi: 10.1038/sj.ejcn.1601412
21. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M, Educational and Clinical Practice Committee, et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr. (2003) 22:415–21. doi: 10.1016/S0161-0432(03)00098-0
22. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. (1993) 85:365–76. doi: 10.1093/jnci/85.5.365
23. Mourtzakis M, Prado CM, Liefers JR, Reiman T, McCargar LJ, Baracos VE, et al. practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. (2008) 33:997–1006. doi: 10.1139/H08-075
24. van Vugt JL, Levolger S, Gharbharan A, Koek M, Niessen WL, Burger JW, et al. A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. J Cachexia Sarcopenia Muscle. (2017) 8:285–97. doi: 10.1002/jcsm.12158
25. Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJ, Goh V. Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity.

Supplementary figure 1
Decision curve analysis (DCA) of the nomogram for predicting low SMD and Low SMI based on the training (n = 1,005) and validation (n = 652) cohorts. (A) The DCA for low SMD predictions in the training cohort. (B) The DCA for low SMD predictions in the validation cohort. (C) The DCA for low SMI predictions in the training cohort. (D) The DCA for low SMI predictions in the validation cohort.
Obesity may impact on clinical outcome. *Insights Imaging.* (2015) 6:489–97. doi: 10.1007/s11244-015-0414-0

26. Singh N, Baby D, Rajaguru JP, Patil PB, Thakkarnavar SS, Pujari VB. Inflammation and cancer. *Ann Afr Med.* (2019) 18:121–6. doi: 10.4103/aaam.aaam_56_18

27. Kroenke CH, Prado CM, Meyerhardt JA, Weltzien EK, Xiao J, CSepedes Feliciano EM, et al. Muscle radioactivity and mortality in patients with colorectal cancer. *Cancer.* (2018) 124:3008–15. doi: 10.1002/cncr.31405

28. Fujisawa N, Nakagawa H, Kudo Y, Tateishi R, Tagami M, Watadani T, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. *J Hepatol.* (2015) 63:131–40. doi: 10.1016/j.jhep.2015.02.031

29. Mardiani Y, Yano Y, Ratnasari N, Choridah L, Setyawan NH, et al. “Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study”. *Molecular Cancer.* (2019) 18:135. doi: 10.1186/s12953-019-0768-2

30. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc.* (2014) 15:95–101. doi: 10.1016/j.jamda.2013.11.025

31. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Combor KK, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. *J Natl Compr Canc Netw.* (2018) 16:359–69. doi: 10.6004/jnccn.2018.0021

32. Iasonos A, Schrag D, Raj GV, Panagia N. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol.* (2008) 26:1364–70. doi: 10.1200/JCO.2007.12.9791

33. Go SL, Park MJ, Song HN, Kang MH, Park HI, Jeon KN, et al. Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer. *Support Care Cancer.* (2016) 24:2075–84. doi: 10.1007/s00520-015-2997-x

34. Shu Y, Qin M, Song Y, Tang Q, Huang Y, Shen P, et al. M2 polarization of tumor-associated macrophages is dependent on integrin beta3 via peroxisome proliferator-activated receptor gamma up-regulation in breast cancer. *Immunology.* (2020) 160:345–56. doi: 10.1111/imm.13196

35. Grenader T, Nash S, Plotkin Y, Furuse J, Mizuno N, Okusaka T, et al. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced and recurrent setting. *Front Oncol.* (2020) 10:415. doi: 10.3389/fonc.2020.00415

36. Kantola T, Klimstrup K, Vayrynen JP, Vornanen J, Bloigu R, Karhu T, et al. Stage-dependent alterations of the serum cytokine pattern in colorectal cancer. *Br J Cancer.* (2012) 107:1729–36. doi: 10.1038/bjc.2012.456

37. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. *Science.* (2000) 289:2365–6. doi: 10.1126/science.289.5488.2363

38. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. *Cell Metab.* (2012) 16:153–66. doi: 10.1016/j.cmet.2012.06.011

39. Goodpaster BH, Bergman RB, Clark RV, Goodpaster BH, Bergman RC, Clark RV, et al. Myosteatosis in the context of skeletal muscle function deficit: an interdisciplinary workshop at the national institute on aging. *Front Physiol.* (2020) 11:963. doi: 10.3389/fphys.2020.00963

40. Miljkovic I, Zmuda JM. Epidemiology of myosteatosis. *Curr Opin Clin Nutr Metab Care.* (2010) 13:260–4. doi: 10.1097/MCO.0b013e3283375b28

41. Delmonico MJ, Harris TB, Lee JS, Visser M, Nevitt M, Kritchevsky SB, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. *J Am Geriatr Soc.* (2007) 55:769–74. doi: 10.1111/j.1532-5415.2007.01140.x

42. Stout MB, Justice NC, Nicklas BJ, Kirkland JL. Physiological aging: links among adipose tissue dysfunction, diabetes, and frailty. *Physiology.* (2017) 32:9–19. doi: 10.1152/physiol.00012.2016

43. Stangl MK, Becker W, Chubanov V, Ferrari U, Fischereider M, Gudermann T, et al. Sarcopenia-endocrinological and neurological aspects. *Exp Clin Endocrinol Diabetes.* (2019) 127:8–22. doi: 10.1055/a-0672-1007

44. Weinberg MS, Shachar SS, Mus H, Deal AM, Popuri K, Yu H, et al. Beyond sarcopenia: characterization and integration of skeletal muscle quantity and radioactivity in a curable breast cancer population. *Breast J.* (2018) 24:278–84. doi: 10.1111/tbj.12952

45. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Rubenoff R. Skeletal muscle endpoints associated with elevated physical disability risk in older men and women. *Am J Epidemiol.* (2009) 169:413–21. doi: 10.1093/aje/kwp058

46. Cao J, Xu H, Li W, Guo Z, Lin Y, Shi Y, et al. Nutritional assessment and risk factors associated to malnutrition in patients with esophageal cancer. *Cancer Probl Cancer.* (2021) 45:108638. doi: 10.1016/j.curpbcancer.2020.108638

47. Moreau J, Ordan MA, Barbe C, Mazza C, Perrier M, Betsen D, et al. Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. *Cancer Med.* (2019) 8:3677–84. doi: 10.1002/cam4.2238

48. Souza NC, Gonzalez MC, Martucci RB, Rodrigues VD, de Pinho NR, Qureshi AR, et al. Comparative analysis between computed tomography and surrogate methods to detect low muscle mass among colorectal cancer patients. *J Parenter Enteral Nutr.* (2020) 44:1328–37. doi: 10.1002/jpen.1741

49. Iannuzzi-Succich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. *J Gerontol A Biol Sci Med Sci.* (2002) 57:M772–7. doi: 10.1093/gerona/57.12.M772

50. Beavers KM, Beavers DP, Houston DK, Harris TB, Hue TF, Koster AR, et al. Associations between body composition and gait-speed decline: results from the health, aging, and body composition study. *Am J Clin Nutr.* (2013) 97:552–60. doi: 10.3945/ajcn.112.074860

51. Rantanen T, Masaki K, Foley D, Izmirlian G, White L, Guralnik JM. Grip strength changes over 27 yr in Japanese-American men. *J Appl Physiol.* (1985) 58:2047–53. doi: 10.1152/jappl.1985.58.6.2047

52. Ro HJ, Kim DK, Lee SY, Seo KM, Kang SH, Sub HC. Relationship between respiratory muscle strength and conventional sarcopenic indices in young adults: a preliminary study. *Ann Rehabil Med.* (2013) 37:880–7. doi: 10.5535/arm.2013.37.6.880

53. Kera T, Kawai H, Hirano H, Kojima M, Watanabe Y, Motokawa K, et al. Definition of respiratory sarcopenia with peak expiratory flow rate. *J Am Med Dir Assoc.* (2019) 20:1021–5. doi: 10.1016/j.jamda.2018.12.013

54. Kera T, Kawai H, Hirano H, Kojima M, Fujiwara Y, Ihara K, et al. Relationships among peak expiratory flow rate, body composition, physical function, and sarcopenia in community-dwelling older adults. *Aging Clin Exp Res.* (2018) 30:331–40. doi: 10.1007/s40520-017-0777-9